When was Enodia Therapeutics founded?

Enodia Therapeutics was founded in 2025 and raised its 1st funding round 1 year after it was founded.

Where is Enodia Therapeutics located?

Enodia Therapeutics is headquartered in Paris, France.

How many employees does Enodia Therapeutics have?

As of Sep 30, 2026, the latest employee count at Enodia Therapeutics is 16.

Is Enodia Therapeutics a funded company?

Enodia Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 08, 2026.

When was the latest funding round of Enodia Therapeutics?

Enodia Therapeutics' latest funding was a $***** Seed round on Jan 08, 2026, with participation from 9 investors.

Where does Enodia Therapeutics rank among its competitors?

Enodia Therapeutics ranks 160th amongst 421 active competitors, of which 141 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Enodia Therapeutics, which secured $25M in Jan, 2026.

Who are the top competitors of Enodia Therapeutics?

Enodia Therapeutics' top competitors include BeiGene, Biogen and argenx. Among them, Enodia Therapeutics secured the most recent funding round in January, 2026.

Enodia Therapeutics - 2026 Company Profile, Funding & Competitors

Company Details

Developer of small-molecule therapies for inflammatory and autoimmune diseases. The company specializing in small-molecule therapies for targeted protein degradation at the point of synthesis via the Sec61 translocon. The company targets disease-driving secreted and membrane proteins, primarily for immuno-inflammatory and autoimmune disorders, with expansion potential into oncology and viral infections.

Key Metrics

Founded Year

2025

Location

Paris, France

Stage

Seed

Total Funding

$25M in 1 round

Latest Funding Round

Seed, Jan 08, 2026, $*****

Investors

Elaia & 9 more

Ranked

160^th among 421 active competitors

Employee Count

16 as on Sep 30, 2026

Similar Companies

BeiGene & 491 more

View Enodia Therapeutics' full profile

Enodia Therapeutics has raised a total funding of $25M over 1 round. Its latest funding round was a Seed round on Jan 08, 2026 for $*****. 9 investors participated in its latest round. Enodia Therapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Enodia Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 08, 2026	5263388	Seed	2957214	8519622	9420268	8983579

Access funding benchmarks and valuations. Sign up today!

View details of Enodia Therapeutics's funding rounds and investors

Enodia Therapeutics' employee count trend

Enodia Therapeutics has 16 employees as of Sep 26. Here is Enodia Therapeutics's employee count trend over the years:

Employee count trend for Enodia Therapeutics

Uncover Enodia Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Enodia Therapeutics include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Enodia Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
8th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
9th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
160th	Enodia Therapeutics 2025, Paris (France), Seed	Developer of small-molecule therapies for inflammatory and autoimmune diseases	$25M	Mission BioCapital, Pfizer & 8 others	39/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Enodia Therapeutics's competitors? Click here to see the top ones

Enodia Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Enodia Therapeutics's sector:

Free

Immunology - Sector Report

Edition: July, 2026 (69 Pages)

View all reports related to Enodia Therapeutics

Media has covered Enodia Therapeutics for a total of 10 events in the last 1 year, 3 of them have been about company updates and 1 about partnerships.